scholarly journals Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting

2021 ◽  
Author(s):  
Kerri Basile ◽  
Rebecca J Rockett ◽  
Kenneth McPhie ◽  
Michael Fennell ◽  
Jessica Johnson-Mackinnon ◽  
...  
Keyword(s):  
World Health Organization ◽  
Receptor Binding ◽  
Neutralizing Antibody ◽  
Spike Protein ◽  
World Health ◽  
Receptor Binding Domain ◽  
Limited Ability ◽  
The World ◽  
Antibody Titres ◽  
Health Organization

In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired 15 mutations in the receptor binding domain of the spike protein, raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected 1, 3, and 6 months post-two doses of Pfizer-BioNTech BNT162b2 has a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralizing antibody titres are boosted. Despite this increase, neutralising antibody titres are reduced 4-fold for Omicron compared to lineage A.2.2 SARS-CoV-2.

Binding Profile Assessment of N501Y: a More Infectious Mutation on the Receptor Binding Domain of SARS-CoV-2 Spike Protein

2021 ◽  
Author(s):  
Yuzhao Zhang ◽  
Xibing He ◽  
Viet Hoang Man ◽  
Jingchen Zhai ◽  
Beihong Ji ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Rna Virus ◽  
Md Simulations ◽  
Binding Domain ◽  
Spike Protein ◽  
World Health ◽  
Receptor Binding Domain ◽  
Binding Profile ◽  
New Variant ◽  
The World

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 and has accumulated nearly a hundred million reported infections thereafter. This highly transmissible and pathogenic coronavirus has caused a pandemic of acute respiratory disease, coronavirus disease 2019 (COVID-19), which has caught extensive attention and greatly changed people’s lifestyles all over the world. As an RNA virus, SARS-CoV-2 mutates rapidly as the virus replicates. The world health organization is now closely monitoring the emergence of a new variant, N501Y, on the spike protein. This N501Y variant is found to have higher transmission ability and infectivity, and is believed to be related to the rapid increase of COVID-19 cases in December 2020 in the UK. It was recently reported that the N501Y variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. The Tyr mutation at 501 is located at the receptor binding domain (RBD) of the spike protein, the area that directly contacts human ACE2 (hACE2). It’s urgent to figure out the driving force of the new mutant’s enhanced infectivity. Thus, a computational aided binding profile prediction is made to investigate the binding affinity alteration and potential structural change of the N501Y mutant. <a>The resulting structures of N501Y mutant from MD simulations could be used to develop drug inhibitors against hACE2/RBD binding. </a></p>

scholarly journals An Overview on Lambda, Epsilon, Kappa, Iota and Zeta Variants of Covid-19 and its Probability to Merge with Delta & Delta Plus, why it is a Concern

2021 ◽  
Vol 12 (5) ◽  
pp. 6895-6914
Keyword(s):  
World Health Organization ◽  
Neutralizing Antibodies ◽  
Spike Protein ◽  
World Health ◽  
South American ◽  
Infected Person ◽  
High Prevalence ◽  
The World ◽  
Health Organization

COVID-19 is caused by the virus SARS-CoV-2 that belongs to the Corona groups. The subgroups of the coronavirus families are α, β, γ, and δ coronavirus. On June 15, 2021, the string λ of SARS-CoV-2 was evaluated as a variant of interest via the World Health Organization. This string has a high prevalence in some parts of South American countries, but it occurred only occasionally in Brazil. This study confirms that mutations in the λ -spike protein can be destroyed the neutralizing antibodies and increase infectivity. Coronaviruses such as SARS-CoV-2 have an evolutionary superpower called “recombination” which permits the mixing of their genomes into novel combinations. Unlike regular mutation, which precedes slowly one change at a time, recombination can produce whole changes in a coronavirus genome. Although right now, δ-variant is a concern, a mixing of λ with other variants such as δ-variant is much more of a concern compared to alone variants. There is another item: the recombination can arise within the sample after it was taken from the infected person, not while it was inside their body.

scholarly journals Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals

2021 ◽  
Author(s):  
Diego Alejandro Alvarez-Diaz ◽  
Ana L Munoz ◽  
Pilar Tavera-Rodriguez ◽  
Maria T Herrera-Sepulveda ◽  
Hector A Ruiz-Moreno ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Spike Protein ◽  
World Health ◽  
The World ◽  
Need To Evaluate ◽  
Surveillance Programs ◽  
Antibody Titers ◽  
Epidemiological Impact ◽  
Health Organization

Background Global surveillance programs for the virus that causes COVID-19 are showing the emergence of variants with mutations in the Spike protein, including the Mu variant, recently declared as a Variant of Interest (VOI) by the World Health Organization. Because these types of variants can be more infectious or less susceptible to antiviral treatments and vaccine-induced antibodies. Objectives To evaluate the sensitivity of the Mu variant (B.1.621) to neutralizing antibodies induced by the BNT162b2 vaccine. Study design Three of the most predominant SARS-CoV-2 variants in Colombia during the epidemiological peaks of 2021 were isolated. Microneutralization assays were performed by incubating 120 TCDI50 of each SARS-CoV-2 isolate with five 2-fold serial dilutions of sera from 14 BNT162b2 vaccinated volunteers. The MN50 titer was calculated by the Reed-Muench formula Results The three isolated variants were Mu, a Variant of Interest (VOI), Gamma, a variant of concern (VOC), and B.1.111 that lacks genetic markers associated with greater virulence. At the end of August, the Mu and Gamma variants were widely distributed in Colombia. Mu was predominant (49%), followed by Gamma (25%). In contrast, B.1.111 became almost undetectable. The evaluation of neutralizing antibodies suggests that patients vaccinated with BNT162-2 generate neutralizing antibody titers against the Mu variant at significantly lower concentrations relative to B.1.111 and Gamma. Conclusions This study shows the importance of continuing with surveillance programs of emerging variants as well as the need to evaluate the neutralizing antibody response induced by other vaccines circulating in the country against Mu and other variants with high epidemiological impact.

scholarly journals Binding Profile Assessment of N501Y: a More Infectious Mutation on the Receptor Binding Domain of SARS-CoV-2 Spike Protein

2021 ◽  
Author(s):  
Yuzhao Zhang ◽  
Xibing He ◽  
Viet Hoang Man ◽  
Jingchen Zhai ◽  
Beihong Ji ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Rna Virus ◽  
Md Simulations ◽  
Binding Domain ◽  
Spike Protein ◽  
World Health ◽  
Receptor Binding Domain ◽  
Binding Profile ◽  
New Variant ◽  
The World

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 and has accumulated nearly a hundred million reported infections thereafter. This highly transmissible and pathogenic coronavirus has caused a pandemic of acute respiratory disease, coronavirus disease 2019 (COVID-19), which has caught extensive attention and greatly changed people’s lifestyles all over the world. As an RNA virus, SARS-CoV-2 mutates rapidly as the virus replicates. The world health organization is now closely monitoring the emergence of a new variant, N501Y, on the spike protein. This N501Y variant is found to have higher transmission ability and infectivity, and is believed to be related to the rapid increase of COVID-19 cases in December 2020 in the UK. It was recently reported that the N501Y variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. The Tyr mutation at 501 is located at the receptor binding domain (RBD) of the spike protein, the area that directly contacts human ACE2 (hACE2). It’s urgent to figure out the driving force of the new mutant’s enhanced infectivity. Thus, a computational aided binding profile prediction is made to investigate the binding affinity alteration and potential structural change of the N501Y mutant. <a>The resulting structures of N501Y mutant from MD simulations could be used to develop drug inhibitors against hACE2/RBD binding. </a></p>

scholarly journals Binding Profile Assessment of N501Y: a More Infectious Mutation on the Receptor Binding Domain of SARS-CoV-2 Spike Protein

2021 ◽  
Author(s):  
Yuzhao Zhang ◽  
Xibing He ◽  
Viet Hoang Man ◽  
Jingchen Zhai ◽  
Beihong Ji ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Rna Virus ◽  
Md Simulations ◽  
Binding Domain ◽  
Spike Protein ◽  
World Health ◽  
Receptor Binding Domain ◽  
Binding Profile ◽  
New Variant ◽  
The World

<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019 and has accumulated nearly a hundred million reported infections thereafter. This highly transmissible and pathogenic coronavirus has caused a pandemic of acute respiratory disease, coronavirus disease 2019 (COVID-19), which has caught extensive attention and greatly changed people’s lifestyles all over the world. As an RNA virus, SARS-CoV-2 mutates rapidly as the virus replicates. The world health organization is now closely monitoring the emergence of a new variant, N501Y, on the spike protein. This N501Y variant is found to have higher transmission ability and infectivity, and is believed to be related to the rapid increase of COVID-19 cases in December 2020 in the UK. It was recently reported that the N501Y variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. The Tyr mutation at 501 is located at the receptor binding domain (RBD) of the spike protein, the area that directly contacts human ACE2 (hACE2). It’s urgent to figure out the driving force of the new mutant’s enhanced infectivity. Thus, a computational aided binding profile prediction is made to investigate the binding affinity alteration and potential structural change of the N501Y mutant. <a>The resulting structures of N501Y mutant from MD simulations could be used to develop drug inhibitors against hACE2/RBD binding. </a></p>

Erstes Instrument zur standardisierten Erfassung der Teilhabe Behinderter

2017 ◽  
Vol 79 (07) ◽  
pp. 526-527
Keyword(s):  
World Health Organization ◽  
World Health ◽  
The World ◽  
Health Organization ◽  
Menschen Mit Behinderung

Coenen M et al. [Recommendation for the collection and analysis of data on participation and disability from the perspective of the World Health Organization]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59: 1060–1067 Um eine gleichberechtigte Teilhabe an der Gesellschaft von Menschen mit Behinderung zu ermöglichen, werden zunächst Daten zu vorhandenen Einschränkungen gebraucht. Erst wenn diese detailliert erhoben wurden, können Konzepte zur Beseitigung von Problemen entwickelt werden. Ein standardisiertes Erhebungsinstrument für alle Aspekte der Funktionsfähigkeit fehlte jedoch bisher.

Sign in / Sign up

Export Citation Format

Share Document